Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Condition:   Healthy Volunteers (Meningococcal Infection) Interventions:   Biological: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine (MenACYW conjugate vaccine);   Biological: Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®);   Biological: Diphtheria, Tetanus, Acellular Pe rtussis, Poliovirus and Haemophilus b Vaccine;   Biological: Pneumococcal 13-valent Conjugate Vaccine;   Biological: Rotavirus Vaccine;   Biological: Hepatitis B Vaccine;   Biological: Measles, Mumps, and Rubella Virus Vaccine;   Biological: Varicella Virus Vaccine Sponsor:   Sanofi Pasteur, a Sanofi Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials